Invokana™ (canagliflozin): Risk of diabetic ketoacidosis

Janssen would like to inform healthcare professionals of the risk of diabetic ketoacidosis (DKA) during treatment with sodium glucose co-transporter 2 (SGLT2) inhibitors, including Invokana™. Serious and sometimes life-threatening cases of DKA in patients treated with SGLT2 inhibitors have been reported, with the majority of them requiring hospitalization. The presentation of DKA in a number of cases was atypical in that glucose levels were only mildly elevated at less than 11 mmol/L (or 200 mg/dL), while DKA typically occurs at glucose levels greater than 14 mmol/L (or 250 mg/dL). Healthcare professionals are advised to assess the patients, who are taking SGLT2 inhibitors, for ketoacidosis when they present with signs or symptoms of metabolic acidosis in order to prevent delayed diagnosis and patient management.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.